About Lucid Diagnostics
Lucid Diagnostics is a publicly listed company based in New York (United States) founded in 2018. Diagnostic kits for esophageal cancer biomarkers are developed. The company has 72 employees. Lucid Diagnostics has completed 1 acquisition, including CapNostics. Lucid Diagnostics offers products and services including EsoGuard and EsoCheck. Its focus areas include Life Sciences, Oncology, In-Vitro Diagnostic Tests and Gastrointestinal Cancer. Its legal entity is LUCID DIAGNOSTICS INC. Its competitors include PAVmed, Previse and CapNostics; 2 of its 3 listed competitors have raised funding.
Company details
Lucid Diagnostics was founded in 2018 in New York, United States, within the medical diagnostics sector. A non-invasive testing platform is provided by the company to identify esophageal cancer biomarkers. EsoGuard is employed to detect 31 methylated DNA markers associated with Barretts esophagus. EsoCheck functions as a device for collecting targeted esophageal cells. Operations focus on advancing early detection methods for gastrointestinal conditions.
- Headquarters New York, United States
- Employees 72
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website luciddx.com
- Social LinkedIn X YouTube
- Legal Name Lucid Diagnostics Inc.
- Annual Revenue$4.71 M (USD)8.28as on Dec 31, 2025
- Net Profit-$58.01 M (USD)-27.41as on Dec 31, 2025
- EBITDA-$48.77 M (USD)-8.65as on Dec 31, 2025
- Latest Funding Round$15M (USD), Post-IPO
Oct 2026
- Employee Count72
- Investments & Acquisitions
Products & Services of Lucid Diagnostics
Lucid Diagnostics offers a comprehensive portfolio of products and services, including EsoGuard and EsoCheck.
DNA test for early detection of esophageal precancer without endoscopy.
Tool for identifying esophageal precancer risks in office visits.
Apps and channels of Lucid Diagnostics
its YouTube channel Lucid Diagnostics has 91 subscribers and 20 videos.
Videos from Lucid Diagnostics
The most watched videos on Lucid Diagnostics's YouTube channel, Lucid Diagnostics (91 subscribers). Click a video to play it here.
More on Lucid Diagnostics.
Funding Insights of Lucid Diagnostics
- Total Rounds 3
- Last Round Post-IPO — $15M
- First Round $13.63M
(Mar 2023)
All 3 funding rounds of Lucid Diagnostics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct 2026 | $15M | Post-IPO | – | – | – |
| Oct 2023 | $5M | Post-IPO | – | – | – |
| Mar 2023 | $13.63M | Post-IPO | – | – | – |
People of Lucid Diagnostics
43 people are tracked at Lucid Diagnostics (13 in leadership, 11 in board & advisors, 19 in team); the tracked headcount is 72.
| Name | Role | Group |
|---|---|---|
Lishan Aklog | CEO | Leadership |
Dennis M. Mcgrath | CFO | Leadership |
John Rubano | Senior Vice President of Sales | Leadership |
Jenna Mowatt | VP, Marketing & Communications | Leadership |
Matt Riley | Senior Director, Investor Relations | Leadership |
Shaun O'Neil | President and COO | Leadership |
David Wurtman | CMO | Leadership |
Jim Fricchione | Vice President, Employer Markets | Leadership |
Joe Erfort | Sr. Region Director, West | Leadership |
Michael Lautersack | Senior Area Sales Director | Leadership |
Diane H. | Area Vice President – US West | Leadership |
Erica Austin | Senior Director Of First Responder Partnerships | Leadership |
Alena Androsenka | Sr. Director, Revenue Cycle Management | Leadership |
Nick Shaheen | Chair | Board & advisors |
Gary Falk | Medical Advisor | Board & advisors |
Sandy Markowitz | Strategic Advisor | Board & advisors |
Anthony Infantolino | Medical Advisor | Board & advisors |
Amitabh Chak | Medical Advisor | Board & advisors |
Michael Smith | Medical Advisor | Board & advisors |
Stan Lapidus | Strategic Advisor | Board & advisors |
23 more people are available in the full profile.
Complete people profiles for Lucid Diagnostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Lucid Diagnostics
Lucid Diagnostics is a publicly listed company on the NASDAQ with ticker symbol LUCD in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date14 Oct 2021
- Listed onNASDAQ: LUCD
- Listed entityLucid Diagnostics Inc.
- Exchange sectorHealth technology
- ISINUS54948X1090
- Share price$0.61 (+1.44% on the day) · 2026-10-13
- Market capitalisation$123.2M
- EPS (diluted, trailing year)$-0.47
- Volume (last session)1,096,500
Financials of Lucid Diagnostics
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $4.7M | -$58.0M | -$48.8M |
| 2024 | $4.3M | -$45.5M | -$44.9M |
| 2023 | $2.4M | -$52.7M | -$46.0M |
| 2022 | $377,000 | -$56.2M | -$54.2M |
| 2021 | $500,000 | -$28.1M | -$27.4M |
Detailed financial statements for Lucid Diagnostics
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Lucid Diagnostics
Lucid Diagnostics has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include CapNostics.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
FDA-cleared swallowable device is used for non-endoscopic GI screening. | capnostics.com | Newtown Square, United States | 2013 | Oct 2021 | •••• |
Complete acquisition details for Lucid Diagnostics
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Lucid Diagnostics
5 dated milestones of Lucid Diagnostics across 8 years, from founding to its latest funding, stage changes and deals.
- Founded Lucid Diagnostics is founded.
- Acquisition Acquires CapNostics.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $13.6M.
- Funding Latest funding round, Post-IPO, of $15.0M.
Competitors of Lucid Diagnostics
Lucid Diagnostics has 3 listed competitors in our database, 2 of them funded. They include PAVmed, Previse and CapNostics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| pavmed.com | 2014 | New York, United States | $845,000 | 107 | Developer of medical devices and biomarkers to detect various diseases | |
| previsedx.com | 2018 | Baltimore, United States | $5.39M | Cancer detection and prevention solutions are developed by Previse. | ||
| capnostics.com | 2013 | Newtown Square, United States | FDA-cleared swallowable device is used for non-endoscopic GI screening. |
Detailed competitors of Lucid Diagnostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Lucid Diagnostics
The website of Lucid Diagnostics (luciddx.com) receives about 4.5K visits a month.
- Monthly visits4.5K
▲ 19.7% vs previous month
Top companies in Gastroenterology
3 companies that operate in the same segment as Lucid Diagnostics (Gastroenterology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Therapeutics for gastrointestinal disorders, including linaclotide, are developed. | 1998 | Cambridge, Massachusetts, United States | USD 206.25 M | USD 296.15 M | 253 | |
Sacral neuromodulation devices are developed for urinary and bowel control. | 2013 | Irvine, California, United States | USD 143.47 M | |||
Provider of a deep learning platform for detecting circulating cancer-related markers | 2014 | United States | USD 1.35 B | 411 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Lucid Diagnostics
Complete news archive for Lucid Diagnostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Lucid Diagnostics
Lucid Diagnostics was founded in 2018 and raised its 1st funding round 5 years after it was founded.
Lucid Diagnostics is headquartered in New York, United States. It is registered at New York, New York, United States.
Lucid Diagnostics has 72 employees.
Annual revenue of Lucid Diagnostics is $4.71M as on Dec 31, 2025.
Lucid Diagnostics was founded in 2018 in New York, United States, within the medical diagnostics sector. A non-invasive testing platform is provided by the company to identify esophageal cancer biomarkers. EsoGuard is employed to detect 31 methylated DNA markers associated with Barretts esophagus. EsoCheck functions as a device for collecting targeted esophageal cells. Operations focus on advancing early detection methods for gastrointestinal conditions.
Lucid Diagnostics's top competitors include PAVmed, Previse and CapNostics.
Lucid Diagnostics offers EsoGuard and EsoCheck.
Yes, Lucid Diagnostics is publicly traded on NASDAQ under the ticker symbol LUCD.
Lucid Diagnostics has made 1 acquisition, including CapNostics.
Lucid Diagnostics operates through Lucid Diagnostics Inc..